Vectora LAI now covers the reported net sales of long-acting injectables.

Company-reported net sales by asset, year and zone, FY2021 to FY2025, in Atlas, with every filter of the LAI landscape.


FY2025 WORLDWIDE	EXCLUDING INCRETINS	FISCAL YEARS
$107.6B	$35.6B	5

Worldwide reported net sales. Scope: 101 marketed LAI assets, 57 of them with a reported figure for FY2025.

Source: Vectora LAI sales base · worldwide company-reported net sales, FY2021–FY2025

Excluding incretins, reported LAI net sales grew from $25.1B to $35.6B.

Half-life extension grew **+60%**, drug delivery systems +30%. Incretins, shown apart, reached $72.0B in 2025.



Vectora LAI

Source: Vectora LAI sales base · worldwide company-reported net sales, FY2021–FY2025

The same $35.6B, cut four ways.

FY2025 reported net sales, excluding incretins.

TECHNOLOGY



Drug delivery system **$19.2B** Half-life extension **$16.5B**

ROUTE OF ADMINISTRATION




IM **$11.6B** SC **$10.2B** IV **$6.4B** Two routes **$4.5B** Local routes **$2.9B**

MOLECULE TYPE



Other biologic **$12.7B** Small molecule **$12.0B** Peptide **$8.0B** Antibody **$2.2B**
Nucleic acid **$0.7B**

EFFECT




Systemic **$33.0B** Local **$1.8B** Mixed **$0.8B**

Source: Vectora LAI sales base · worldwide company-reported net sales, FY2021–FY2025

Haematology runs on biologics, CNS on small molecules, endocrinology on peptides.

FY2025 reported net sales by therapeutic area and API class, excluding incretins.




An asset with several therapeutic areas counts in each.

Source: Vectora LAI sales base · worldwide company-reported net sales, FY2021–FY2025

Nanocrystals and PEGylation lead their branches.

FY2025 reported net sales by technology family and effect, excluding incretins.




Two mechanisms: ALTUVIIIO (Fc fusion + XTEN) and Rolvedon (Fc fusion + PEGylation). Each asset counts once.

Source: Vectora LAI sales base · worldwide company-reported net sales, FY2021–FY2025

Atlas now includes a Sales lens.

Split reported net sales by therapeutic area, technology, route, API class or company, with incretins in or out, and see which assets are behind every total.



Every figure carries its source. Every gap carries its reason.

Company-reported net sales for long-acting injectables, FY2021 to FY2025, by asset, zone and year, in Atlas.

Request access

vectora-lai.com